Designing phage therapeutics

Current Pharmaceutical Biotechnology

Volumn 11, Issue 1, 2010, Pages 15-27

  Goodridge, Lawrence D ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Genetic engineering; Phage cocktails; Rational design

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; OUTER MEMBRANE PROTEIN A; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL GENETICS; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM ISOLATION; BURN INFECTION; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EAR INFECTION; ESCHERICHIA COLI; EYE INFECTION; GASTROINTESTINAL INFECTION; GENETIC ENGINEERING; GENETIC MANIPULATION; HOST RANGE; IN VITRO STUDY; LYSOGENIZATION; NONHUMAN; OSTEOMYELITIS; PLANT GROWTH; PSEUDOMONAS INFECTION; REVIEW; SALMONELLA; SKIN INFECTION; VIRION; WOUND DRESSING; WOUND INFECTION;

BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DRUG DESIGN; GENETIC ENHANCEMENT; HUMANS; VIRAL VACCINES;

EID: 77950156511     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110790725348     Document Type: Review

References (97)

1. Gill, J. J.; Hyman, P. Phage choice, isolation and preparation for phage therapy. Curr. Pharm. Biotechnol., 2010, 11(1), 2-14.
2. Kurzepa, A.; Dabrowska, K.; Switała-Jeleń, K.; Górski, A. Molecular modification of T4 bacteriophage proteins and its potential application - review. Folia Microbiol., (Praha) 2009, 54 (1), 5-15.
3. Brüssow, H. Phage therapy: the Escherichia coli experience. Microbiology (Reading), 2005, 151 (7), 2133-2140.
4. Hyman, P.; Abedon, S. T. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol., 2010, 70, [Epub ahead of print].
5. Lindberg, A. A. Bacteriophage receptors. Ann. Rev. Microbiol., 1973, 27, 205-241.
6. Stirm, S. Phage-receptor relationship reminiscent of the Vi II system. Nature, 1968, 10, 637-639.
7. Edwards, S.; Meynell, G. G. The widespread occurence of enteric flagellar phages. J. Gen. Virol., 1968, 2 (3), 443-444.
8. Coyette, J.; Ghuysen, J. M. Structure of the cell wall of Staphylococcus aureus, strain Copenhagen. IX. Teichoic acid and phage adsorption. Biochemistry, 1968, 7 (6), 2385-2389.
9. Montag, D.; Hashemolhosseini, S.; Henning, U. Receptor-recognizing proteins of T-even type bacteriophages. The receptor-recognizing area of proteins 37 of phages T4. J. Mol. Biol., 1990, 216 (2), 327-334.
10. Henning, U.; Hashemolhosseini, S. Receptor Recognition by T-even Type Coliphages. In: The Molecular Biology of Bacteriophage T4, Karam, J. D., Ed.; ASM Press: Washington, DC, 1994, pp. 291-298.
11. Hashemolhosseini, S.; Montag, D.; Kramer, L.; Henning, U. Determinants of receptor specificity of coliphages of the T4 family : A chaperone alters the host range. J. Mol. Biol., 1994, 241 (4), 524-533.
12. Hashemolhosseini, S.; Holmes, Z.; Mutschler, B.; Henning, U. Alterations of receptor specificities of coliphages of the T2 family. J. Mol. Biol., 1994, 240 (2), 105-110.
13. Wilson, J. H.; Lugtig, R. B.; Wood, W. B. Interaction of bacteriophage T4 tail fiber components with lipopolysaccharide fraction from Escherichia coli. J. Mol. Biol., 1970, 51 (2), 423-434.
14. Heller, K. J. Molecular interactions between bacteriophage and the Gram-negative cell envelope. Arch. Microbiol., 1992, 158 (4), 235-248.
15. Balogh, B.; Jones, J. B.; Iriarte, F. B.; Momol, M. T. Phage therapy for plant disease control. Curr. Pharm. Biotechnol., 2010, 11(1), 48-57.
16. Kudva, I. T.; Jelacic, S.; Tarr, P. I.; Youderian, P.; Hovde, C. J. Biocontrol of Escherichia coli O157 with O157-specific bacteriophages. Appl. Environ. Microbiol., 1999, 65 (9), 3767-3773.
17. Abedon, S. T.; Thomas-Abedon, C. Phage therapy pharmacology. Curr. Pharm. Biotechnol., 2010, 11(1), 28-47.
18. Raya, R. R.; Varey, P.; Oot, R. A.; Dyen, M. R.; Callaway, T. R.; Edrington, T. S.; Kutter, E. M.; Brabban, A. D. Isolation and characterization of a new T-even bacteriophage, CEV1, and determination of its potential to reduce Escherichia coli O157:H7 levels in sheep. Appl. Environ. Microbiol., 2006, 72 (9), 6405-6410.
19. Andreatti F.R.L.; Higgins, J. P.; Higgins, S. E.; Gaona, G.; Wolfenden, A. D.; Tellez, G.; Hargis, B. M. Ability of bacteriophages isolated from different sources to reduce Salmonella enterica serovar Enteritidis in vitro and in vivo. Poult. Sci., 2007, 86 (9), 1904-1909.
20. Toro, H.; Price, S. B.; McKee, A. S.; Hoerr, F. J.; Krehling, J.; Perdue, M.; Bauermeister, L. Use of bacteriophages in combination with competitive exclusion to reduce Salmonella from infected chickens. Avian Dis., 2005, 49 (1), 118-124.
21. Harris, D. L. Reduction of Salmonella by bacteriophage treatment - NPB # 99-230 - The effect of bacteriophage treatment as an intervention strategy to reduce the rapid dissemination of Salmonella typhimurium in experimentally infected pigs; National Pork Board: 2000.
22. McVay, C. S.; Velasquez, M.; Fralick, J. A. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother., 2007, 51 (6), 1934-1938.
23. Kutter, E. M.; DeVos, D.; Gvasalia, G.; Alavidze, Z.; Gogokhia, L.; Kuhl, S.; Abedon, T. S. Phage therapy in clinical practice: treatment of human infection. Curr. Pharm. Biotechnol., 2010, 11(1), 69-86.
24. Hanlon, G. W. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob. Agents, 2007, 30 (2), 118-128.
25. Markoishvili, K.; Tsitlanadze, G.; Katsarava, R.; Morris, J. G. Jr.; Sulakvelidze, A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol., 2002, 41 (7), 453-458.
26. Jikia, D.; Chkhaidze, N.; Imedashvili, E.; Mgaloblishvili, I.; Tsitlanadze, G.; Katsarava, R.; Glenn Morris, J. J.; Sulakvelidze, A. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin. Exp. Dermatol., 2005, 30 (1), 23-26.
27. Tanji, Y.; Shimada, T.; Yoichi, M.; Miyanaga, K.; Hori, K.; Unno, H. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl. Microbiol. Biotechnol., 2004, 64 (2), 270-274.
28. Tanji, Y.; Shimada, T.; Fukudomi, H.; Miyanaga, K.; Nakai, Y.; Unno, H. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J. Biosci. Bioeng., 2005, 100 (3), 280-287.
29. Chase, J.; Kalchayanard, N.; Goodridge, L. D. Use of bacteriophage therapy to reduce Escherichia coli O157:H7 concentrations in an anaerobic digestor that simulates the bovine gastrointestinal tract. Institute of Food Technologists Annual Meeting and Food Expo, New Orleans, Louisiana 2005.
30. Ackermann, H.-W.; Krisch, H. M. A catalogue of T4-type bacteriophages. Arch. Virol., 1997, 142 (12), 2329-2345.
31. Tétart, F.; Desplats, C.; Kutateladze, M.; Monod, C.; Ackermann, H.-W.; Krisch, H. M. Phylogeny of the major head and tail genes of the wide-ranging T4-type bacteriophages. J. Bacteriol., 2001, 183 (1), 358-366.
32. Henning, U.; Jann, K. Two-component nature of bacteriophage T4 receptor activity in Escherichia coli K-12. J. Bacteriol., 1979, 137 (1), 664-666.
33. Lenski, R. E. Two-step resistance by Escherichia coli B to bactreriophage T2. Genetics, 1984, 107 (1), 1-7.
34. Yu, S. L.; Ding, H. W.; Seah, J. N.; Wu, K. M.; Chang, Y. C.; Tam, M. F.; Syu, W., Jr. Characterization of a phage specific to hemorrhagic Escherichia coli O157:H7 and disclosure of variations in host outer membrane protein OmpC. J. Biomed. Sci., 1998, 5, 370-382.
35. Goodridge, L.; Gallaccio, A.; Griffiths, M. W. Morphological, host range, and genetic characterization of two coliphages. Appl. Environ. Microbiol., 2003, 69 (9), 5364-5371.
36. Beher, M. G.; Pugsley, A. P. Coliphage which requires either the LamB protein or the OmpC protein for adsorption to Escherichia coli K-12. J. Virol., 1981, 38 (1), 372-375.
37. Scholl, D.; Rogers, S.; Adhya, S.; Merril, C. R. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol., 2001, 75 (6), 2509-2515.
38. Morona, R.; Henning, U. Host range mutants of bacteriophage Ox2 can use two different outer membrane proteins of Escherichia coli K-12 as receptors. J. Bacteriol., 1984, 159 (2), 579-582.
39. Moreno, F.; Wandersman, C. OmpC and LamB proteins can serve as substitute receptors for host range mutants of coliphage TuIa. J. Bacteriol., 1980, 144 (3), 1182-1185.
40. Liu, M.; Deora, R.; Doulatov, S. R.; Gingery, M.; Eiserling, F. A.; Preston, A.; Maskell, D. J.; Simons, R. W.; Cotter, P. A.; Parkhill, J.; Miller, J. F. Reverse transcriptase-mediated tropism switching in Bordetella bacteriophage. Science, 2002, 295 (5562), 2091-2094.
41. Uhl, M. A.; Miller, J. F. Integration of multiple domains in a two-component sensor protein: the Bordetella pertussis BvgAS phosphorelay. EMBO J., 1996, 15, 1028-1036.
42. Plasterk, R. H.; Ilmer, T. A.; van de Putte, P. Site-specific recombination by gin of bacteriophage Mu: Inversions and deletions. Virology, 1983, 127 (1), 24-36.
43. st ed, Calendar, R., Ed.; Plenum Press: New York, 1988, Vol. 1, pp. 193-234.
44. Abedon, S. T. Bacteriophage evolution and ecology. Adv. Appl. Microbiol., 2009, 67, 1-45.
45. Hendrix, R. W. Phage Evolution. In: Bacteriophage Ecology; Abedon, S. T., Ed.; Cambridge University Press: Cambridge, UK, 2008, pp. 177-194.
46. Sandmeier, H. Acquisition and rearrangement of sequence motifs in the evolution of bacteriophage tail fibres. Mol. Microbiol., 1994, 12 (3), 343-350.
47. Haggard-Ljungquist, E.; Halling, C.; Calendar, R. DNA sequences of the tail fiber genes of bacteriophage P2: evidence for horizontal transfer of tail fiber genes among unrelated bacteriophages. J. Bacteriol., 1992, 174 (5), 1462-1477.
48. Botstein, D. A theory of molecular evolution for bacteriophages. Ann. N. Y. Acad. Sci., 1980, 354, 484-490.
49. Tétart, F.; Repoila, F.; Monod, C.; Krisch, H. M. Bacteriophage T4 host range is expanded by duplications of a small domain of the tail fiber adhesin. J. Mol. Biol., 1996, 258 (5), 726-731.
50. Tétart, F.; Desplats, C.; Krisch, H. M. Polymorphism of the T-even bacteriophage distal tail fiber locus: Recombination between conserved motifs swaps adhesin specificities. J. Mol. Biol., 1998.
51. Tétart, F.; Desplats, C.; Krisch, H. M. Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesin specificity. J. Mol. Biol., 1998, 282 (3), 543-556.
52. Yoichi, M.; Abe, M.; Miyanaga, K.; Unno, H.; Tanji, Y. Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. J. Biotechnol., 2005, 115 (1), 101-107.
53. Kerr, B.; West, J.; Bohannan, B. J. M. Bacteriophage: Models for Exploring Basic Principles of Ecology. In: Bacteriophage Ecology; Abedon, S. T., Ed.; Cambridge University Press: Cambridge, UK, 2008, pp. 31-63.
54. Buckling, A.; Rainey, P. B. Antagonistic coevolution between a bacterium and a bacteriophage. Proc. R. Soc. Lond. B Biol. Sci., 2002, 269 (1494), 931-936.
55. Mizoguchi, K.; Morita, M.; Fischer, C. R.; Yoichi, M.; Tanji, Y.; Unno, H. Coevolution of bacteriophage PP01 and Escherichia coli O157:H7 in continuous culture. Appl. Environ. Microbiol., 2003, 69 (1), 170-176.
56. Harcombe, W. R.; Bull, J. J. Impact of phages on two-species bacterial communities. Appl. Environ. Microbiol., 2005, 71(9), 5254-5259.
57. Smith, H. W.; Huggins, M. B. Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. J. Gen. Microbiol., 1982, 128 (2), 307-318.
58. Levin, B.R.; Bull, J.J. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am. Nat., 1996, 147 (6), 881-898.
59. Skiena, S. S. Designing better phages. Bioinformatics, 2001, 17 (Suppl 1), S253-S261.
60. Norris, J. S.; Westwater, C.; Schofield, D. Prokaryotic gene therapy to combat multidrug resistant bacterial infection [editorial]. Gene Ther., 2000, 7 (9), 723-725.
61. Holcík, M.; Iyer, V. N. Conditionally lethal genes associated with bacterial plasmids. Microbiology, 1997, 143 (11), 3403-3416.
62. Kuowei, W.; Wood, T. K. Evaluation of the hok/sok killer locus for rnhanced plasmid stability. Biotechnol. Bioeng., 1994, 44, 912-921.
63. Jensen, R. B.; Gerdes, K. Programmed cell death in bacteria: proteic plasmid stabilization systems. Mol. Mirobiol., 1995, 17, 205-210.
64. Gerdes, K.; Gultyaev, A. P.; Franch, K.; Pedersen, K.; Mikkelsen, N. D. Antisense RNA-regulated programmed cell death. Ann. Rev. Genet., 1997, 31, 1-31.
65. Couturier, M.; Bahassi, E. M.; Van Meldern, L. Bacterial death by DNA gyrase poisoning. Trends Microbiol., 1998, 6, 269-275.
66. Engelberg-Kulka, H.; Glaser, G. Addiction modules and programmed cell death and antideath in bacterial cultures. Ann. Rev. Microbiol., 1999, 53, 43-70.
67. Poulsen, L. K.; Larsen, N. W.; Molin, S.; Andersson, P. A family of genes encoding a cell-killing function may be conserved in all gram-negative bacteria. Mol. Microbiol., 1989, 3, 1463-1472.
68. Masuda, Y.; Miyakawa, K.; Nishimura, Y.; Ohtsubo, E. chpA and chpB, Escherichia coli chromosomal homologs of the pem locus responsible for stable maintenance of plasmid R100. J. Bacteriol., 1993, 175, 6850-6856.
69. Feng, J.; Yamanaka, K.; Niki, H.; Ogura, T.; Hiraga, S. New killing system controlled by two gene located immediately upstream of the mukB gene in Escherichia coli. Mol. Gen. Genet., 1994, 243, 136-147.
70. Aizenman, E.; Engelberg-Kulka, H.; Glaser, G. An Escherichia coli chromosomal "addiction module" regulated by guanosine [corrected] 3′,5′-bispyrophosphate: a model for programmed bacterial cell death. Proc. Natl. Acad. Sci. USA, 1996, 93, 6059-6063.
71. Gotfredsen, M.; Gerdes, K. The Escherichia coli relBE genes belong to a new toxin-antitoxin gene family. Mol. Microbiol., 1998, 29, 1065-1076.
72. Westwater, C.; Kasman, L. M.; Schofield, D. A.; Werner, P. A.; Dolan, J. W.; Schmidt, M. G.; Norris, J. S. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother., 2003, 47 (4), 1301-1307.
73. Hagens, S.; Habel, A.; von Ahsen, U.; von Gabain, A.; Bläsi, U. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother., 2004, 48 (10), 3817-3822.
74. Fairhead, H. Small acid-soluble proteins and uses thereof. 20040097705, 2004.
75. Fairhead, H. Antimicrobial compositions and uses thereof. WO 2004113375, 2004.
76. Toxin-phage bacteriocide as an antibiotic therapy, Rowland Institute of Harvard: 2002.
77. Atsumi, S.; Little, J. W. Regulatory circuit design and evolution using phage λ. Genes Dev., 2004, 18 (17), 2086-2094.
78. Costerton, J.; Stewart, P.; Greenberg, E. Bacterial biofilms: a common cause of persistent infections. Science, 1999, 284 (5418), 1318-1322.
79. Lu, T. K.; Collins, J. J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. USA, 2007, 104 (27), 11197-11202.
80. Embleton, M. L.; Nair, S. P.; Cookson, B. D.; Wilson, M. Selective lethal photosensitization of methicillin-resistant Staphylococcus aureus using an IgG-tin (IV) chlorin e6 conjugate. J. Antimicrob. Chemother., 2002, 50 (6), 857-864.
81. Embleton, M. L.; Nair, S. P.; Heywood, W.; Menon, D. C.; Cookson, B. D.; Wilson, M. Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus. Antimicrob. Agents Chemother., 2005, 49 (9), 3690-3696.
82. Yacoby, I.; Shamis, M.; Bar, H.; Shabat, D.; Benhar, I. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob. Agents Chemother., 2006, 50 (6), 2087-2097.
83. Yacoby, I.; Bar, H.; Benhar, I. Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob. Agents Chemother., 2007, 51 (6), 2156-2163.
84. Cao, J.; Sun, Y.; Berglindh, T.; Mellgard, B.; Li, Z.; Mardh, B.; Mardh, S. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. Biochim. Biophys. Acta, 2000, 1474 (1), 107-113.
85. Hagens, S.; Bläsi, U. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett. Appl. Microbiol., 2003, 37 (4), 318-323.
86. Zhang, X.; McDaniel, A. D.; Wolf, L. E.; Keusch, G. T.; Waldor, M. K.; Acheson, D. W. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis., 2000, 181 (2), 664-670.
87. Ramachandran, J.; Padmanabhan, S.; Sriram, B. Incapacitated wholecell immunogenic bacterial compositions. 2002, 6913753 B2.
88. Ramachandran, J.; Padmanabhan, S.; Sriram, B. Lysin-deficient bacteriophages having reduced immunogenicity. 2002, 6,896,882 B2.
89. Krylov, V. N. Phage therapy in terms of bacteriophage genetics: Hopes, prospects, safety, limitations. Rus. J. Genet., 2001, 37(7), 715-730.
90. Rapson, M. E.; Burdent, F. A.; Glancy, L. P.; Hogson, D. A.; Mann, N. H. Bacteriophages useful for therapy and prophylaxis of bacterial infections. WO03080823, 2003.
91. Stent, G. S. Molecular Biology of Bacterial Viruses; WH Freeman and Co.: San Francisco, CA, 1963.
92. Appelmans, R. Le Bacteriophage dans l'organisme. Comp. Rend. Soc. de Biol., 1921, 85, 722-724.
93. Evans, A. C. Inactivation of antistreptococcus bacteriophage by animal fluids. Public Health Rep., 1933, 48, 411-426.
94. Nungester, W. J.; Watrous, R. M. Accumulation of bacteriophage in spleen and liver following its intravenous inoculation. Proc. Soc. Exp. Biol. Med., 1934, 31, 901-905.
95. Merril, C. R.; Biswas, B.; Carlton, R.; Jensen, N. C.; Creed, G. J.; Zullo, S.; Adhya, S. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA, 1996, 93 (8), 3188-3192.
96. Kim, K.-P.; Cha, J.-D.; Jang, E.-H.; Klumpp, J.; Hagens, S.; Hardt, W.-D.; Lee, K.-Y.; Loessner, M. J. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol., 2008, 1 (3), 247-257.
97. Hagens, S.; Loessner, M. J. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr. Pharm. Biotechnol., 2010, 11(1), 58-68.